U.S. market Closed. Opens in 16 hours 47 minutes

NVCR | NovoCure Limited Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for NVCR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is frighteningly weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -22.19 48.85
PEG Ratio (TTM) -1.94 4.32
P/S Ratio (TTM) 5.75 13.46
P/B Ratio (TTM) 9.21 7.20
P/FCF Ratio (TTM) -42.47 221.33
Price to 5YR AVG Earnings Ratio -46.91 105.61
Price to 5YR AVG FCF Ratio 244.60 95.82

Profitability (0%)

Company Industry
ROA (TTM) -12.26% 6.68%
ROE (TTM) -41.48% 11.29%
Net Profit Margin (TTM) -25.93% -0.48%
ROIC 5YR AVG -10.51% 11.30%

Growth (83%)

4QTR AVG 3YR AVG 5YR AVG
EPS 11.52% 26.01% -20.14%
Revenue 5.08% 30.19% 17.16%
Net Income 11.21% 22.67% -22.86%
Cash Flow 176.39% 594.42% 276.46%

Health (16%)

Company Industry
Current Ratio (TTM) 1.49 3.23
Quick Ratio (TTM) 1.44 2.45
D/E Ratio (TTM) 1.81 0.51
Interest Coverage (TTM) -17.33 38.76
Piotroski F-Score 1 6
Altman Z-Score 1.61 26.47
LTL to 5YR AVG FCF 43.90 4.24
Shares Outstanding Growth 5YR AVG 3.00% 0.91%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙